2023-05-04 08:56:54 ET
- Silence Therapeutics ( NASDAQ: SLN ) announced that AstraZeneca had nominated the first product candidate under its siRNA collaboration and will pay Silence a $10M option fee to advance development on an undisclosed program.
- Silence and AstraZeneca began collaborating in March 2020 to develop siRNA therapeutics using Silence's mRNAi GOLD platform for various diseases.
- The agreement includes up to ten targets, with AstraZeneca paying Silence a $10 million option fee per selected target at the time of nomination.
- Silence could receive up to $140 million in development milestones and up to $250 million in commercialization milestones per target, as well as tiered royalties on net sales ranging from high single digit to low double digit.
- Press Release
For further details see:
Silence Therapeutics receives $10M milestone payment from AstraZeneca collaboration